Pharmacists,

On Wednesday, February 8th, the Feiba dosing recommendations for warfarin reversal will be updated in Cerner to include increased doses for patients with warfarin-associated intracranial hemorrhage. Previously, Feiba dosing for warfarin reversal consisted of 500 units or 1000 units (depending on INR) for all life-threatening bleeds. The updates will separate Feiba indication into "Intracranial Hemorrhage" and "All other life-threatening bleeds." Both the "HOSP Emergent Reversal of Anticoagulants" and the "FEIBA for Emergent Reversal of Anticoagulants" Power Plans will be updated to reflect these changes. Specific dosing recommendations are in the chart below, as well as in the attached documents. These updated documents will also be linked under the "Comments" section when searching Feiba on FormWeb following implementation. The pharmacist verification process will remain the same for all other Feiba orders. Please do not hesitate to contact me with questions regarding these updates.